Was the Columbus Blue Jackets' 6-year, $36 million contract for Charlie Coyle an overpay?

In evaluating whether the Columbus Blue Jackets' six-year, $36 million contract for Charlie Coyle constitutes an overpay, several factors must be analyzed: Coyle's age and production, the team's current needs and roster strategy, and the broader market context.

1. Player Evaluation and Age Considerations:

Charlie Coyle, a versatile forward capable of playing both center and wing, has been recognized for his strong two-way play and leadership qualities. However, at the time of signing, Coyle is in his early 30s, a phase where many players begin to experience a decline in athletic performance. This is significant when committing to a long-term contract that extends into a player's late 30s. Historically, contracts for players in this age range can become challenging for teams if the player's performance regresses faster than anticipated. Thus, the potential risk of diminished returns over the latter years of the contract is certainly present.

2. Team Strategy and Rebuilding Phase:

For a team like the Blue Jackets, purportedly in a rebuilding phase, Coyle's role must be considered in the context of mentorship and stability for younger players. If his presence is deemed essential for developing prospects or stabilizing the forward lineup, then the investment might be justified by the team's strategic goals. However, if the rebuild necessitates flexibility and cap space for future acquisitions, this investment could be seen as restrictive, especially if Coyle's performance doesn't align with the financial commitment.

3. Market Considerations:

Examining the NHL market, a $6 million average annual value (AAV) for a player like Coyle is moderately high, particularly given his stats in relation to other players receiving similar pay. While seasoned and versatile, Coyle does not produce at the elite level, typically expected from players commanding top salaries. Comparisons with similarly aged players and contracts can offer insight into whether this aligns with the market trend or if it's an outlier.

Conclusion:

In conclusion, whether this contract is an overpay largely hinges on Coyle's ability to maintain productivity and contribute to the Blue Jackets' long-term objectives. If he sustains his performance and adds intangible benefits (like leadership), the contract might fit strategically; however, if performance dips or if financial constraints limit future flexibility, the contract risks being an overvaluation that could impede the Blue Jackets' adaptability in the evolving NHL landscape. Ultimately, the contract's merit will be judged by Coyle's ability to impact the team positively over its duration and the overall alignment with the Blue Jackets' vision for their future.

My take: Fair market value, but risky term.

At $6M AAV, Coyle isn't dramatically overpaid. He's a reliable two-way center with versatility to play wing or center—exactly the type of player teams value in the playoffs. Comparable middle-six centers regularly sign in the $5-7M range.

The concern isn't the annual salary—it's the six-year commitment. Coyle will be 34-35 by the end of this deal. If his play declines significantly in years 4-6, Columbus is stuck with a cap anchor during what should be their competitive window post-rebuild.

That said, the Blue Jackets have cap space now and need veteran leadership for their young core. This isn't a cap-crunch team signing a questionable player—it's a rebuilding team using financial flexibility to acquire a known commodity who can mentor their prospects.

Verdict: Not an overpay by current market standards, but the term makes it a gamble. If Coyle remains productive through year 4, this looks smart. If he declines early, it becomes a problematic contract quickly. The safe play would have been 4 years.

Step‑by‑step analysis of the Columbus Blue Jackets’ 6‑year, $36 M deal for Charlie Coyle

1. Market comparison for similar players

Takeaway: A $6 M AAV for a 33‑year‑old who averages ~0.55 P/G sits above the market for purely defensive forwards (Copp, Paul) but below or in line with veterans who still contribute offensively (Staal, Duchene). The contract is therefore premium for a depth/two‑way role, but not an extreme outlier.

2. Value versus production

• Expected points over the term (assuming a modest decline of 0.02 P/G per year, typical for forwards in their mid‑30s):

  • Year 1 (33): 0.55 P/G → ~45 P
  • Year 2 (34): 0.53 → ~43 P
  • Year 3 (35): 0.51 → ~41 P
  • Year 4 (36): 0.49 → ~40 P
  • Year 5 (37): 0.47 → ~38 P
  • Year 6 (38): 0.45 → ~36 P
  • Total ≈ 243 points over 6 years (~40.5 P per season on average).

• Cost per point: $36 M ÷ 243 pts ≈ $148k per point.

  • For reference, recent elite forwards (e.g., McDavid, Draisaitl) run ~ $70k/pt; mid‑tier second‑liners hover $100k–$130k/pt; depth players often exceed $150k/pt.
  • Thus, Coyle’s contract is at the higher end of the cost‑per‑point spectrum for a player expected to produce ~0.5 P/G.

3. Strategic fit for the Blue Jackets

Overall, the signing addresses a leadership/Depth need without crippling cap flexibility.

4. Verdict

• Is it an overpay?
  • Pure production lens: Slightly overpaying relative to point‑per‑dollar metrics; a $5–$5.5 M AAV would align more closely with his expected output.
  • Contextual lens (leadership, versatility, roster construction): The premium buys a reliable two‑way veteran who can help guide a young core, kill penalties, and provide flexibility in lineup construction. In that context, the $6 M AAV is reasonable, not an outright overpay.

Conclusion: The Blue Jackets secured a useful veteran piece at a modest premium. While the contract is not a “bargain” based solely on points, it fits within a sensible range for a player who brings intangible qualities and does not jeopardize the team’s cap situation. The deal is more a strategic investment in stability than a pure overvaluation.